PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

• A. Sharp,
• A. Williams,
• S. Blagden,
• R. Plummer,
• D. Hochhauser,
• M. G. Krebs,
• S. Pacey,
• J. Evans,
• S. Whelan,
• S. Nandakumar,
• S. Rogers,
• K. L. Jameson,
• F. G. Basile,
• J. de Bono,
• H.-T. Arkenau

Affiliations

A. Sharp

1 The Institute of Cancer Research, London, United Kingdom

A. Williams

3 Sarah Cannon Research Institute (SCRI), London

S. Blagden

4 University of Oxford, Oxford

R. Plummer

5 Northern Centre for Care, Newcastle upon Tyne

D. Hochhauser

6 University College London (UCL), London

M. G. Krebs

7 The Christie NHS Foundation Trust

S. Pacey

9 Cambridge Cancer Centre (CCC), Cambridge

J. Evans

10 University of Glasgow, Glasgow, United Kingdom

S. Whelan

11 Nurix Therapeutics, Inc., San Francisco, United States of America

S. Nandakumar

11 Nurix Therapeutics, Inc., San Francisco, United States of America

S. Rogers

11 Nurix Therapeutics, Inc., San Francisco, United States of America

K. L. Jameson

11 Nurix Therapeutics, Inc., San Francisco, United States of America

F. G. Basile

11 Nurix Therapeutics, Inc., San Francisco, United States of America

J. de Bono

12 The Institute of Cancer Research, London, London, United Kingdom

H.-T. Arkenau

3 Sarah Cannon Research Institute (SCRI), London